Moleculin Biotech (MBRX) Stock Price, News & Analysis

Company Overview

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Key Stats

• Today's Range: $1.90 to $1.90
• 50-Day Range: $1.86 to $3.09
• 52-Week Range: $1.81 to $15.75
• Volume: 1,190 shs
• Average Volume: 34,381 shs
• Market Capitalization: $5.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.00
• Consensus Rating: Buy

Moleculin Biotech Stock Analysis - MarketRank™

Moleculin Biotech scored higher than 60% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Moleculin Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Moleculin Biotech has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Moleculin Biotech are expected to grow in the coming year, from ($7.98) to ($5.02) per share.

Price to Book Value per Share Ratio

Moleculin Biotech has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.71% of the float of Moleculin Biotech has been sold short.

Short Interest Ratio / Days to Cover

Moleculin Biotech has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Moleculin Biotech has recently decreased by 61.74%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Moleculin Biotech does not currently pay a dividend.

Dividend Growth

Moleculin Biotech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.71% of the float of Moleculin Biotech has been sold short.

Short Interest Ratio / Days to Cover

Moleculin Biotech has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Moleculin Biotech has recently decreased by 61.74%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.40

News Sentiment

Moleculin Biotech has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Moleculin Biotech this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for MBRX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Moleculin Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.10% of the stock of Moleculin Biotech is held by insiders.

Percentage Held by Institutions

Only 15.52% of the stock of Moleculin Biotech is held by institutions.

MBRX Stock Analysis - Frequently Asked Questions

How have MBRX shares performed this year?

Moleculin Biotech's stock was trading at $12.8760 on January 1st, 2024. Since then, MBRX stock has decreased by 85.2% and is now trading at $1.90.
View the best growth stocks for 2024 here.

How were Moleculin Biotech's earnings last quarter?

Moleculin Biotech, Inc. (NASDAQ:MBRX) posted its quarterly earnings data on Friday, August, 11th. The company reported ($3.00) EPS for the quarter, beating the consensus estimate of ($4.20) by $1.20.

When did Moleculin Biotech's stock split?

Shares of Moleculin Biotech reverse split on Friday, March 22nd 2024. The 1-15 reverse split was announced on Friday, March 22nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Moleculin Biotech?

Shares of MBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Moleculin Biotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Moleculin Biotech investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META) and CymaBay Therapeutics (CBAY).

Company Calendar

• Last Earnings: 8/11/2023
• Today: 12/18/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MBRX
• CUSIP: N/A
• CIK: 1659617
• Web: www.moleculin.com
• Phone: (713) 300-5160
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $24.00
• High Stock Price Target: $40.00
• Low Stock Price Target: $8.00
• Potential Upside/Downside: +1,176.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-29,770,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -157.44%
• Return on Assets: -97.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.08
• Quick Ratio: 2.08

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.70 per share
• Price / Book: 0.16

Miscellaneous

• Outstanding Shares: 3,002,000
• Free Float: 2,789,000
• Market Cap: $5.64 million
• Optionable: Not Optionable
• Beta: 1.87